[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 45px 0px 20px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center”]

Signatures Precision Medicine Program

[/cs_text][x_blockquote cite=”Dr Giselle Sholler” type=”left”]”This is what we want for every patient. We shouldn’t just be waiting until a child is told they are incurable to investigate the best ways to personalize treatment.”[/x_blockquote][cs_text]The launch of a new clinical trial called PEDS-PLAN in September of 2015 marks a paradigm shift in childhood cancer treatment and precision medicine — the first time DNA and RNA sequencing are being done in newly diagnosed patients.

Personalized medicine… precision medicine… molecularly guided therapy (MGT)… genomics. They’re different terms for what is generally the same concept — personalizing treatment per patient based on specific genetic or molecular analysis. In childhood cancer, genomics is being used to beat cancer on a kid by kid basis.[/cs_text][cs_element_video _id=”7″ ][cs_element_text _id=”8″ ][cs_element_accordion _id=”9″ ][cs_element_accordion_item _id=”10″ ][cs_element_accordion_item _id=”11″ ][cs_element_accordion_item _id=”12″ ][cs_element_accordion_item _id=”13″ ][cs_element_accordion_item _id=”14″ ][/cs_element_accordion][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 20px;”][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 20px;”][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 30px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center”]

Precision Medicine Trials

[/cs_text][x_prompt type=”left” title=”NMTRC012″ message=”Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma. OPEN
” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT02559778″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC009″ message=”Molecular-Guided Therapy for Childhood Cancer Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT02162732″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC001″ message=”Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT01355679″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC008″ message=”Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancer CLOSED

” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT01802567″ href_title=”” target=”blank”][x_prompt type=”left” title=”A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma” message=”A Pilot Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma OPEN

” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT01109238″ href_title=”” target=”blank”][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 30px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center”]

History: Our Work with Precision Medicine

[/cs_text][cs_text]The image below is from a detailed blog post written at beatnb.org.[/cs_text][x_image type=”none” src=”https://research.beatcc.org/wp-content/uploads/2019/02/history.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][/cs_column][/cs_row][/cs_section][/cs_content]